Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study of LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring

Next Previous
Trial Profile

A Study of LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin glargine (Primary) ; Insulin lispro (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms PRONTO-Time in Range
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 07 Apr 2023 Primary endpoint has been met. (Change From Baseline in Percentage of Time With Continuous Glucose Monitoring (CGM) Sensor Glucose Values Between 70-180 Milligrams/Deciliter (mg/dL) (3.9-10.0 Millimoles/Liter [mmol/L]) (Both Inclusive) During Daytime Period at Week 12)
  • 07 Apr 2023 Results published in the Diabetes Therapy
  • 24 Feb 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top